Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5329069 | 0.72 | POLB (0.34) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL8552144 | 0.64 | MAPK1 (0.31) | — | |
| SCHEMBL5325733 | 0.62 | IDO1 (0.47) | KDM4EALDH1A1GAAHPGDLMNA | |
| Hydrochloric Acid SCHEMBL5331192 | 0.61 | IDO1 (0.46) | KDM4EALDH1A1GAAHPGDLMNA | |
| SCHEMBL24133763 | 0.59 | PDE4A (0.32) | — | |
| SCHEMBL1473557 | 0.59 | PTPRZ1 (0.38) | ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL5324745 | 0.59 | MAPT (0.36) | KDM4EALDH1A1HPGDLMNATSHR | |
| SCHEMBL1460963 | 0.58 | ALDH1A1 (0.45) | KDM4EALDH1A1 | |
| SCHEMBL1550855 | 0.58 | PGK1 (0.38) | KDM4EALDH1A1GAAHPGDLMNA | |
| Hydrochloric Acid SCHEMBL5327952 | 0.58 | MAPT (0.35) | KDM4EALDH1A1HPGDLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299113-A1 | Metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-12-27 | — | — | US | disclosed |
| WO-2007148113-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299113-A1 | Metabotropic glutamate receptor modulators | GRM1, GRM2, GRM3 | KDM4E 1726/4885ALDH1A1 2824/4885GAA 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.